Articles
  • Review|Open Access

    Hitting a moving target: inhibition of the nuclear export receptor XPO1/CRM1 as a therapeutic approach in cancer

    Maria Sendino, Miren Josu Omaetxebarria, Jose Antonio Rodríguez
    Cellular homeostasis crucially relies on the correct nucleocytoplasmic distribution of a vast number of proteins and RNA molecules, which are shuttled in and out of the nucleus by specialized transport receptors. The nuclear export receptor XPO1, also called CRM1, mediates the translocation of... Read more
    This article belongs to the Special Issue Targeted cancer therapy
    Cancer Drug Resist 2018;1:139-63. | doi:10.20517/cdr.2018.09
    Published on: 19 Sep 2018  | Viewed:431  | Downloaded:35
    +HTML| PDF
  • Review|Open Access

    Glutamine metabolism in cancer therapy

    Tra-Ly Nguyen, Raúl V. Durán
    The amino acid glutamine plays a key role in the metabolism of highly proliferating cells. During malignant transformation, cancer cells modify the consumption and processing of glutamine to sustain cell growth and proliferation. In some cases, these cancer cells become addicted to glutamine.... Read more
    This article belongs to the Special Issue Targeted cancer therapy
    Cancer Drug Resist 2018;1:126-38. | doi:10.20517/cdr.2018.08
    Published on: 19 Sep 2018  | Viewed:349  | Downloaded:51
    +HTML| PDF
  • Review|Open Access

    Molecular bases of Sorcin-dependent resistance to chemotherapeutic agents

    Ilaria Genovese, Andrea Ilari, Theo Battista, Valerio Chiarini, Francesco Fazi, Annarita Fiorillo, Gianni Colotti
    Soluble resistance-related calcium binding protein (Sorcin) is a protein initially labelled “resistance-related”, since it is co-amplified with ABCB1 in multidrug (MD)-resistant cells. While for years Sorcin overproduction was believed to be a by-product of the co-amplification of its gene with... Read more
    This article belongs to the Special Issue Targeted cancer therapy
    Cancer Drug Resist 2018;1:164-80. | doi:10.20517/cdr.2018.10
    Published on: 19 Sep 2018  | Viewed:941  | Downloaded:78
    +HTML| PDF
  • Review|Open Access

    Sphingolipid metabolism and drug resistance in ovarian cancer

    Kelly M. Kreitzburg, Robert C. A. M. van Waardenburg, Karina J. Yoon
    Despite progress in understanding molecular aberrations that contribute to the development and progression of ovarian cancer, virtually all patients succumb to drug resistant disease at relapse. Emerging data implicate bioactive sphingolipids and regulation of sphingolipid metabolism as... Read more
    Cancer Drug Resist 2018;1:181-97. | doi:10.20517/cdr.2018.06
    Published on: 19 Sep 2018  | Viewed:1878  | Downloaded:121
    +HTML| PDF
  • Opinion|Open Access

    Linking tyrosine kinase inhibitor-mediated inflammation with normal epithelial cell homeostasis and tumor therapeutic responses

    Natalia J Gurule, Lynn E. Heasley
    Receptor tyrosine kinases (RTKs) bearing oncogenic mutations in EGFR, ALK and ROS1 occur in a significant subset of lung adenocarcinomas. Tyrosine kinase inhibitors (TKIs) targeting tumor cells dependent on these oncogenic RTKs yield tumor shrinkage, but also a variety of adverse events. Skin... Read more
    This article belongs to the Special Issue Targeted cancer therapy
    Cancer Drug Resist 2018;1:118-25. | doi:10.20517/cdr.2018.12
    Published on: 19 Sep 2018  | Viewed:1106  | Downloaded:122
    +HTML| PDF
Cancer Drug Resistance ISSN 2578-532X (Online)
Partners
Copyright © 2018 OAE Publishing Inc. All Rights Reserved.